The BATF3 Knockout KYSE-30 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human KYSE-30 esophageal squamous cell carcinoma line. This product provides a heterogeneous pool of cells with targeted disruption of the BATF3 gene, generated by electroporation or transfection of CRISPR ribonucleoprotein complexes. The resulting polyclonal population contains a mixture of knockout alleles, offering a robust loss-of-function model for studying BATF3-dependent processes in a cancer background without the need for clonal selection.
KYSE-30 is a well-differentiated, invasive esophageal squamous cell carcinoma cell line established from a 64-year-old male patient. These cells express cytokeratins and epithelial markers, retaining characteristics of the original tumor. As a representative model for esophageal squamous cell carcinoma, KYSE-30 is widely used to investigate oncogenic signaling, tumor progression, and therapeutic responses. The genetic ablation of BATF3 in this context provides insights into the cell-intrinsic roles of a transcription factor more commonly associated with dendritic cell development.
BATF3 encodes a basic leucine zipper transcription factor that heterodimerizes with JUN, FOS, ATF family members, and IRF4/IRF8 to orchestrate gene expression. It is downstream of IRF8 and is activated by cytokines such as GM-CSF and FLT3L, as well as type I interferons and TLR agonists. BATF3 is essential for the differentiation of CD8??+ and CD103+ conventional dendritic cells and drives the expression of IL-12 and MHC class I molecules, thereby promoting antigen cross-presentation and CD8+ T cell priming. In dendritic cells, BATF3 operates within a transcriptional network that includes ID2, ZEB2, and Notch signaling, coordinating the acquisition of cross-presenting capacity.
Although traditionally studied in immune cells, BATF3 expression in cancer cells may influence tumor-immune interactions. Disrupting BATF3 in KYSE-30 cells allows researchers to dissect cancer cell-intrinsic immune signaling pathways and their impact on tumor immunogenicity. The knockout model may exhibit altered MHC class I surface expression and modified responses to interferon signaling, thus affecting T cell recognition. Because KYSE-30 cells lack a functional dendritic cell program, this system enables the investigation of BATF3 functions outside of its canonical role in dendritic cell biology, potentially revealing novel roles in epithelial-derived tumors.
Applications include co-culture assays with T cells or dendritic cells to evaluate immune synapse formation, cytokine profiling to assess changes in type I interferon responses, and RNA-seq analyses to map BATF3-dependent transcriptional networks in carcinoma cells. The polyclonal population is suitable for in vivo tumor growth studies using xenograft or syngeneic models, providing a tool to examine how BATF3 loss in tumor cells influences tumor progression and immune infiltration. Additional uses encompass high-throughput screening of immune checkpoint regulators and validation of BATF3 interaction partners. For more information, please contact Ascent Research.
